The Cryo-Cell Difference

Cryo-Cell’s mission is to provide our clients with the premier stem cell cryopreservation service and to support research and development initiatives for regenerative medicine.

Cryo-Cell was founded in 1989 and was the world's first private cord blood bank to separate and store stem cells in 1992. Today, Cryo-Cell has over 240,000 clients worldwide from 87 countries.

For your cord blood bank comparison, refer to the many advantages and benefits that Cryo-Cell has compared to other cord blood banks.

Since inception, 100% of Cryo-Cell’s specimens have been successfully viable upon thaw.
Accredited by AABB as a cord blood facility, registered with the FDA, cGMP-/cGTP-compliant and ISO 9001:2008 certified.
$75,000 Cryo-Cell Payment Guarantee^SM, along with our $10,000 Cryo-Cell Cares^SM Payment Program.
State-of-the-art, highly monitored secure storage facility, with a redundant back-up diesel generator and 10,000 gallon liquid nitrogen tank.
Client Service Advisors are available 24 hours a day, 7 days a week.
Cord blood cryopreservation storage is in the vapor phase of liquid nitrogen, and the product is overwrapped for an extra layer of protection against cross contamination.
Our cord blood collection bag is the only bag which is FDA & NDA approved.
We use a Heparin-free collection process using CPD, which maximizes stem cell recovery.^[1][2]
White blood cell count is tested pre-processing and post-processing to determine cell recovery for each specimen.
Proprietary cryopreservation work station for the preparation of specimens for transfer and/or transplantation.
Cryo-Cell’s patent pending, menstrual stem cell banking service.
Saneron CCEL Therapeutics, Inc., a Cryo-Cell research affiliate, is dedicated to developing therapeutic applications using stem cells as a treatment option for patients suffering from neurological conditions including Alzheimer’s, Lou Gehrig’s (ALS), and stroke.

¹Recommended in U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: Minimally Manipulated, Unrelated, Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications, published October 2009. It states, “During collection of cord blood, we recommend that you use an appropriate closed, sterile container sealed in a manner that prevents cell loss and contamination. We recommend that you use only citrate-based anticoagulants.”
²Publication discussing benefit of CPD as compared to Heparin: Blood (ASH Annual Meeting Abstracts) American Society of Hematology “Cord Blood Units Collected with Liquid CPD Appear to Contain Significantly More Nucleated and CD34+ Cells Than Units Collected with Dry Heparin” Morey Kraus*, 1, Karen Foster*, 2, Asimena Rigas Bridges*, 3 and Mark C. Walters, MD 4 2009 114: Abstract 4227 http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/4227